We have recently announced the 2016 dates for our International Symposium on Malignant Mesothelioma. In an effort to make it easier for the mesothelioma-affected community across the United States to access life-saving information provided directly from top experts in mesothelioma, in 2016 the Symposium will consist of three individual conferences in three major cities: Houston, […]
On October 14, the SELLAS Life Sciences Group, a biotech company leading a Phase 2 study of the WT1 vaccine, released the study’s promising data. The Meso Foundation had funded part of the Phase 1 portion of this study, the results of which prompted the Department of Defense to also award it a large grant.
The company […]
Last week, at the World Conference on Lung Cancer, Dr. Raffit Hassan presented promising data on a novel agent, anetumab ravtansine, also known as BAY 94-9343. Anetumab ravtansine is an antibody-drug conjugate directed against the target molecule mesothelin which is highly expressed on mesotheliomas.
“Anetumab ravtansine shows encouraging efficacy in patients with advanced mesothelioma which warrants […]
If you attended our International Symposium on Malignant Mesothelioma in March of this year, you may recall the buzz of excitement that coursed throughout the scientific sessions. This buzz sparked excitement throughout the entire mesothelioma community, as we discussed advances in science, the needs of those affected by this disease, and the work being done […]
Over the last several year or so, a number of people have posted information about various supplements they favor, both for general health and, occasionally, as specific alternative remedies meant to bolster cancer treatment or prevention. A number of our mesothelioma warriors have used yoga or stretching regimens to aid in post-surgical tissue relaxation, and […]